Talen
Regeneron and Mammoth announce gene editing partnership worth $370m per target
The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types
Study identifies hundreds of priority targets for cancer drug discovery
Researchers identified 370 priority drug candidates across 27 types of cancer
Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
The companies will develop CRISPR-based therapies for neurological and muscular diseases
Moderna and Life Edit partner to accelerate gene editing therapies
The companies will jointly develop in vivo mRNA therapies for hard-to-treat diseases
New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine
The results were published in a peer-reviewed paper in Nature
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...
Disrupting Cell Engineering with Non-Viral Modalities
Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...
Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline
Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology
Gene Editing and Precision Medicine: The Future of Healthcare?
Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...
Takeda and KSQ Therapeutics to develop immune-based cancer treatments
Collaboration will utilise KSQ’s CRISPR-screening technology
Allergan and Editas claim a CRISPR first in inherited blindness study
Partners are first to use CRISPR to edit cells inside the body